Should the patent system for new medicines be abolished?

@article{Dimasi2007ShouldTP,
  title={Should the patent system for new medicines be abolished?},
  author={Joseph A Dimasi and Henry G. Grabowski},
  journal={Clinical pharmacology and therapeutics},
  year={2007},
  volume={82 5},
  pages={
          488-90
        }
}
“It is hard to think of many industries that have contributed as much to human welfare as the pharmaceutical industry.” This statement was made not by a pharmaceutical industry chief executive officer but by two antitrust regulators, Roy Levy and Abraham Wickelgren, with the Federal Trade Commission.1 There is indeed evidence from the medical and economics literature that new drugs have played a central role in increased longevity, enhanced quality of life, and improved labor-force… CONTINUE READING
BETA

Topics from this paper.

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

Five Nations and the Bill and Melinda Gates Foundation Launch Advanced Market Commitments for Vaccines to Combat Deadly Disease in Poor Nations <http://www

GAVI Alliance
  • vaccineamc.org/media/launch_event_ 01.html>
  • 2007

Measures to enhance access to medical technologies, and new methods of stimulating medical R&D

J. Love
  • U.C. Davis Law Rev
  • 2007

lessons from the Orphan Drug Act

Grabowski, R H.Increasing, D incentives for neglected diseases
  • In International Public Goods, and Transfer of Technology under a Globalized Intellectual Property Regime (eds. Maskus, K.I. & Reichman, J.H.) 457–480
  • 2005

are there more efficient alternatives? are there limitations? Prepared for the Initiative on Public-Private Partnerships Workshop

Ridley, R. G. Product development publicprivate partnerships poverty
  • Combating Diseases Associated with Poverty: Financing Strategies for Product Development and the Potential role of Public–Private Partnerships
  • 2004